Valion Bio Weighs Sale of Velocity Bioworks After Unsolicited Acquisition Interest

• Valion Bio is evaluating a possible sale of Velocity Bioworks following unsolicited acquisition inquiries; discussions with interested parties remain preliminary.
• Any transaction would prioritize retaining production rights and continued manufacturing capabilities for Entolimod, potentially extending to other pipeline assets.
• A sale could provide capital for Entolimod development and other corporate priorities; no transaction has been agreed.
• Velocity will continue operating and pursuing new customers during the strategic review.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Valion Bio Inc. published the original content used to generate this news brief via ACCESS Newswire (Ref. ID: 202610260800ACCESSWRNAPR_____1241450) on October 26, 2026, and is solely responsible for the information contained therein.